Evgen Pharma Share Discussion Threads

[clocktower] 17/1/2024 11:41

T I still not even where it was before the news, so a long long way to go to 1.5/1.7p yet let alone your 4.5p 🤣

[manual dexterity] 17/1/2024 11:39

I've added to my long term holdings today. Good luck

[wololol] 17/1/2024 10:50

I'll miss you Dave. Looking good here, bid starting to rise.

[dave4545] 17/1/2024 10:48

Cenkos on 1.35p bid Shore 1.4p offer next offer 1.65p

Good luck all I'm going offline now.

[the imperialist] 17/1/2024 10:09

Not long now Clock!

[dave4545] 17/1/2024 10:06

5 v 1 now Cenkos on the bid too after 40000 at 1.4p

I'm still not feeling brave enough to buy more. If I had a tiny holding I would be buying but just going to sit on hands and let others if they want to play nibble the 1.4p

[dave4545] 17/1/2024 09:44

Back to NT not that I trust it, briefly went 150k offer.

No move on L2 as of yet 4 v 1, while that looks strong it was that yesterday then bang they all drop together.

Positive but cautious on intraday

[clocktower] 17/1/2024 09:35

No life in the current market, so moving it up would do more damage I guess dave4545.

Has anyone had a response from their enquires about the wording of the non-rns or are they ignoring shareholders whom said they had contacted them yesterday?

[dave4545] 17/1/2024 09:31

I'm surprised Shore have not moved up to 1.5p and gone blue and see if that generates some buying if they really have stock to shift, no risk to them

[wololol] 17/1/2024 09:29

Stalicla video released April this year outlines the timelines for phase 2 studies.https://youtu.be/JyKNwx2uvE8?feature=sharedBoth SPT1 and SPT2 phase 2 study designs from 35 minutes Shows phase 2 trials to start late 2023 early 2024 so all going to plan. SPT2 will naturally follow after SPT1. Let's not forget the SPT1 phase 1 trial was done in 2022 so they will obviously get that going first because they would have had more time to design the trial and then SPT2 in early 2024. All make sense reading yesterday's RNS and watching Staliclas presentations about timelines etc.

[dave4545] 17/1/2024 08:34

Even the mm's are cautious.

In a 1.3p stock you should be able to buy or sell 250k, it has to be one or the other. If you are NT to buy you should be able to sell at least 250k but that is NT too so they are cautious as well.

[wololol] 17/1/2024 08:29

Nearly NT to buy nowfor 30 minutes now. Never known it this long before on this share, hopefully a good sign of a rise incoming. Maybe a Tr1 is in the pipeline. AXA have less than 8 million to sell by my calculations if they do wish to sell it all which can be cleared in a day or two after good news such as this. Once the overhang has gone it could easily re-rate back up to 4p + imo. The only reason it's down here is because of the seller. EVG is currently valued at cash at back which is obviously ridiculously undervalued. The news yesterday has massively de-risked this share as partner Stalicla is fully funded.

[wololol] 17/1/2024 08:11

Are you planning to get 500k shares at 1.5 Dave?

[wololol] 17/1/2024 08:04

I would imagine a 50% rise on the cards at least. The statement confirms Stalicla will get additional SERIES FUNDING FOR SPT2.

[dave4545] 17/1/2024 08:02

NT to buy, lets see what happens

[w t tutte] 17/1/2024 00:17

Odd that this was not mentioned in the RNS - that was clearly a EVG call given this statement from Stalicla.



"Alongside these key developments, Stalicla will further strengthen the package supporting its second precision ASD asset, STP2."

STP2 is SFX-01 .... They would not be highlighting this in a press release if they were planing to drop it and the way it has been worded, with the focus on the package would suggest they expect it to be partnered.

[w t tutte] 17/1/2024 00:00

Not a holder here but the RNS seems to make sense if you listened to the last IM call. In that call they talked about the cash runway in to 2025 had been prudently forecast without the inclusion of any possible Stalicla milestone payments.

It seems to me the point of the RNS was to demonstrate that in the current difficult drug development funding environment that Stalicla is capable of raising capital and thus should be seen as a credible partner. I find it a little odd that they would not include progressing SFX-01 as part of their series B. To me that suggests they will either not proceed or will partner on this asset. Given that EVG LN have chosen to highlight this event it would indicate to me that they are (currently) expecting Stalicla to proceed with SFX-01. I think we may see an announcement at some point that Stalicla will partner SFX-01 development.

[kingalf] 16/1/2024 22:09

Very strange RNS, is Huw trying to give the impression that now Stalicla have raised all this money, Evgen could be inline for a payout ???
Is this what him and Toni were referring to when they said that they were working on adding to shareholder value, creating false impression that will lead to a speculative frenzy so as to suck in more unsuspecting punters.
The whole communication is poorly written and leaves more questions than answers. One certainty is that it adds more weight to the argument that he is out of his depth and a complete amateur.

[clocktower] 16/1/2024 19:42

Wololol unless it is AXA it may not trigger a RNS, someone like markth could easily have 2 million or more to unload but because they are below 3% it is just another trade, I had over that number but sold in smaller trades.

If it is not AXA someone might kick themselves tomorrow if the matter is clarified and it turns out that it was a very poorly written new release.

[lovewinshatelosses] 16/1/2024 19:34

Yep. Validation, Mark. Simple as that. Still too many uncertainties right now, compounded by this utterly uninspiring leadership team. AIMO, naturally.

[wololol] 16/1/2024 19:34

As per the FCA guidelines they must notify if it goes below 3%> they will be under 3% now after that 2 million sale today.https://www.handbook.fca.org.uk/handbook/DTR/5/1.html

[clocktower] 16/1/2024 19:30

I guess that the re-rate would be appropriate because it would reinforce the potential of SFX-01 and the possible longer term huge prize rewards that are at the end of the rainbow, let alone the possibility of new deals and news of the other studies currently progressing, that could lead to one of the big pharmaceutical companies paying top dollar.

In fact it would certainly pay someone to step in now, as I guess they could pick it up for 5p a share or less.

[dave4545] 16/1/2024 19:16

I see a 2 mil sale did the damage at 1.35p when 1.5-1.8p

Hoping to see a RNS from them or can they stay silent if they have gone under 3% ?